Read Entire Disclaimer
Crown Equity Holdings, CRWE, Derma Sciences, Eaton Corp, ETN, Nasdaq:DSCI, NYSE:ETN, NYSE:PFE, otc:crwe, pfe, Pfizer
Diversified industrial manufacturer Eaton Corporation (NYSE:ETN) reported record net income per share of $1.12 for the second quarter of 2012, an increase of 15 percent over the $0.97 earned in the second quarter of 2011.
Sales in the second quarter were $4.1 billion, slightly below the second quarter of 2011. Net income in the second quarter was $382 million compared to $336 million in 2011.
*********
The latest addition to the web marketing is the usage of videos to advertise the product or company. Videos are getting popular because it sends the message effectively to the web users like never before.
Crown Equity Holdings Inc., (CRWE) recenly launched CRWE Tube, www.crwetube.com, a video sharing site that allows billions of people around the world to upload, watch and share original videos.
CRWE offers advertising branding and marketing services as a worldwide online multi-media publisher with its digital network of websites and focuses on the distribution of information for the purpose of bringing together a targeted audience and the advertisers that want to reach them.
CRWE‘s advertising services cover and connect a range of marketing specialties, as well as provide search engine optimization for clients interested in online media awareness.
More about CRWE at www.crownequityholdings.com.
*********
Pfizer Inc. (NYSE:PFE) reported that top-line results for Lyrica® (pregabalin) capsules Study A0081147 – Long Term Safety and Efficacy of Pregabalin in Subjects with Generalized Anxiety Disorder (GAD) – demonstrate that drug discontinuation symptoms were low after tapering Lyrica treatment following three months and six months in GAD patients.
The European Medicines Agency (EMA) requested this study to investigate the relationship between dose and duration of treatment on discontinuation symptoms, including rebound anxiety, following long-term treatment with Lyrica in GAD patients. Pfizer will continue to further analyze these top-line results.
Lyrica is approved for the treatment of GAD in adults in the European Union and several other regions around the world, but not in the United States.
GAD is a chronic, debilitating illness characterized by excessive anxiety and worry for at least six months in duration. Often lasting longer than five years, GAD symptoms are both psychological (anxious mood, heightened fears, feelings of tension, difficulty concentrating) and physical (fatigue, pain, feelings of weakness, gastrointestinal disturbance, palpitations, sleep disturbance and restlessness).
*********
Derma Sciences, Inc. (Nasdaq:DSCI), a medical device and pharmaceutical company focused on advanced wound care, reported the issuance of patents 8,207,233 and 8,207,234 by the U.S. Patent and Trademark Office.
These patents provide additional intellectual property protection for the Company’s investigational drug DSC127 by describing the angiotensin peptide in a specific formulation and a method of using the same to treat diabetic foot ulcers.
***************************
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. BestOtc.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer ( http://bestotc.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold BestOTC.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE) advertises for a particular client, Crown Equity Holdings Inc. (CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE), if paid in stock, can and may sell those securities during the advertising period.
